Introduction and welcome
Congress Presentation
About the speaker
Associate Professor Erik Lerkevang Grove
4 more presentations in this session
DOAC-related bleeding: demographics, risk factors & guidelines .
Speaker: Professor J. Oldgren (Uppsala, SE)
Specific reversal agent for FXa - Inhibitor treatment - What the study data reveals? .
Speaker: Doctor A. Cohen (London, GB)
From clinical evidence to patient management- How to reverse DOAC in clinical practice .
Speaker: Professor S. Middeldorp (Amsterdam, NL)
Plenary questions and discussion
Speaker: Professor E. Lindhoff-Last (DE) Associate Professor E. Grove (Aarhus, DK)
Access the full session
Paradigm shift in DOAC reversal - What are the current therapeutic options?
About the event
ESC 365 is supported by
